The identification of clinical candidate SB-480848:: A potent inhibitor of lipoprotein-associated phospholipase A2

被引：102

作者：

Blackie, JA ^{[1
]}

Bloomer, JC ^{[1
]}

Brown, MJB ^{[1
]}

Cheng, HY ^{[1
]}

Hammond, B ^{[1
]}

Hickey, DMB ^{[1
]}

Ife, RJ ^{[1
]}

Leach, CA ^{[1
]}

Lewis, VA ^{[1
]}

Macphee, CH ^{[1
]}

Milliner, KJ ^{[1
]}

Moores, KE ^{[1
]}

Pinto, IL ^{[1
]}

Smith, SA ^{[1
]}

Stansfield, IG ^{[1
]}

Stanway, SJ ^{[1
]}

Taylor, MA ^{[1
]}

Theobald, CJ ^{[1
]}

机构：

[1] GlaxoSmithKline, Med Res Ctr, Stevenage SG1 2NY, Herts, England

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2003年 / 13卷 / 06期

关键词：

D O I：

10.1016/S0960-894X(03)00058-1

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Modification of the pyrimidone 5-substituent in clinical candidate SB-435495 has given a series of inhibitors of recombinant lipoprotein-associated phospholipase A(2) with sub-nanomolar potency. Cyclopentyl fused derivative 21, SB-480848, showed an enhanced in vitro and in vivo profile versus SB-435495 and has been selected for progression to man. (C) 2003 Elsevier Science Ltd. All rights reserved.

引用

页码：1067 / 1070

页数：4

共 9 条

[1] The discoverv of SB-435495:: A potent, orally active inhibitor of lipoprotein-associated phospholipase A2 for evaluation in man
Blackie, JA
Bloomer, JC
Brown, MJB
Cheng, HY
Elliott, RL
Hammond, B
Hickey, DMB
Ife, RJ
Leach, CA
Lewis, VA
Macphee, CH
Milliner, KJ
Moores, KE
Pinto, IL
Smith, SA
Stansfield, IG
Stanway, SJ
Taylor, MA
Theobald, CJ
Whittaker, CM
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (18) : 2603 - 2606
[2] 1-(Arylpiperazinylamidoalkyl)-pyrimidones:: Orally active inhibitors of lipoprotein-associated phospholipase A2
Bloomer, JC
Boyd, HF
Hickey, DMB
Ife, RJ
Leach, CA
Macphee, CH
Milliner, KJ
Pinto, IL
Rawlings, DA
Smith, SA
Stansfield, IG
Stanway, SJ
Taylor, MA
Theobald, CJ
Whittaker, CM
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) : 1925 - 1929
[3] 2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2
Boyd, HF
Flynn, ST
Hickey, DMB
Ife, RJ
Jones, M
Leach, CA
Macphee, CH
Milliner, KJ
Rawlings, DA
Slingsby, BP
Smith, SA
Stansfield, IG
Tew, DG
Theobald, CJ
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (04) : 395 - 398
[4] N-1 substituted pyrimidin-4-ones:: Novel, orally active inhibitors of lipoprotein-associated phospholipase A2
Boyd, HF
Fell, SCM
Flynn, ST
Hickey, DMB
Ife, RJ
Leach, CA
Macphee, CH
Milliner, KJ
Moores, KE
Pinto, IL
Porter, RA
Rawlings, DA
Smith, SA
Stansfield, IG
Tew, DG
Theobald, CJ
Whittaker, CM
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (22) : 2557 - 2561
[5] GHOSH C, 1984, J ORG CHEM, V49, P5257
[6] Inflammation and atherosclerosis
Libby, P
Ridker, PM
Maseri, A
[J]. CIRCULATION, 2002, 105 (09) : 1135 - 1143
[7] Macphee Colin H., 2001, Current Opinion in Pharmacology, V1, P121, DOI 10.1016/S1471-4892(01)00024-8
[8] Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease.
Packard, CJ
O'Reilly, DSJ
Caslake, MJ
McMahon, AD
Ford, I
Cooney, J
Macphee, CH
Suckling, KE
Krishna, M
Wilkinson, FE
Rumley, A
Lowe, GDO
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (16) : 1148 - 1155
[9] Suckling Keith E, 2002, Expert Opin Ther Targets, V6, P309

← 1 →